← The Wire
TSHANasdaq
Taysha Gene Therapies, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1806310
Develops AAV-based gene therapies for severe monogenic central nervous system diseases
$1.64B
Market cap
$6.73
Last close
+6.2%
1D
+3.1%
5D
5.6M
Volume
Price · last 39 sessions+1.4%
May 4L $5.18 · H $6.98Jun 29
155
Total filings
Jun 25, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · Company UpdateJun 25, 2026424B5424B5Jun 25, 2026424B5424B5Jun 24, 20268-KReg FD Disclosure · Company UpdateJun 22, 20268-KShareholder VoteJun 2, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 202610-K10-KMar 19, 20268-KResults of OperationsMar 19, 20268-KMaterial Agreement · Results of OperationsNov 4, 202510-Q10-QNov 4, 20258-KCompany UpdateOct 16, 20258-KCompany UpdateOct 9, 20258-KCompany UpdateOct 2, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KBylaw Amendment · Shareholder VoteJun 3, 20258-KMaterial Agreement · Company UpdateMay 29, 2025424B5424B5May 29, 20258-K/AReg FD Disclosure · Company UpdateMay 29, 2025424B5424B5May 28, 20258-KReg FD Disclosure · Company UpdateMay 28, 202510-Q10-QMay 15, 20258-KResults of OperationsMay 15, 2025DEFA14ADEFA14AApr 21, 2025DEF 14ADEF 14AApr 21, 202510-K10-KFeb 26, 20258-KResults of OperationsFeb 26, 2025SC 13GTAYSHA GENE THERAPIES, INC.Nov 14, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 22, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KMaterial Agreement · Company UpdateJun 26, 2024424B5424B5Jun 26, 20248-KResults of Operations · Company UpdateJun 26, 2024424B5424B5Jun 26, 20248-KReg FD DisclosureJun 18, 20248-KShareholder VoteMay 30, 20248-KResults of OperationsMay 14, 202410-Q10-QMay 14, 2024DEFA14ADEFA14AApr 18, 2024DEF 14ADEF 14AApr 18, 20248-KResults of OperationsMar 19, 202410-K10-KMar 19, 2024SC 13GTAYSHA GENE THERAPIES, INC.Feb 14, 20248-KReg FD DisclosureJan 10, 20248-KExecutive ChangeDec 20, 20238-KBylaw Amendment · Shareholder VoteNov 15, 20238-KResults of OperationsNov 14, 202310-Q10-QNov 14, 20238-KExecutive ChangeNov 1, 2023DEF 14ADEF 14AOct 5, 20238-KReg FD DisclosureSep 26, 20238-KCompany UpdateSep 19, 20238-KCompany UpdateAug 29, 2023SC 13GSC 13GAug 28, 2023SC 13GSC 13GAug 25, 2023SC 13GSC 13GAug 25, 20238-KCompany UpdateAug 24, 202310-Q10-QAug 14, 20238-KMaterial Agreement · Results of OperationsAug 14, 20238-KDelisting NoticeAug 4, 20238-KReg FD DisclosureJul 31, 20238-KReg FD DisclosureJun 28, 20238-KShareholder VoteJun 23, 20238-KExecutive ChangeJun 22, 20238-KExecutive ChangeJun 6, 20238-KCompany UpdateJun 5, 20238-KCompany UpdateMay 19, 20238-KResults of OperationsMay 15, 202310-Q10-QMay 11, 2023DEFA14ADEFA14AMay 8, 2023DEF 14ADEF 14AMay 8, 20238-KDelisting Notice · Executive ChangeApr 27, 202310-K/A10-K/AApr 27, 2023
Insider Activity
In the 90 days to Feb 4, 2026: 3 sold $4.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 4, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 | $7K |
| Jan 26, 2026 | Nolan Sean P.Chief Executive Officer | Sell | 41,312 | $4.61 | $190K |
| Jan 26, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 26,918 | $4.61 | $124K |
| Jan 26, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 23,849 | $4.61 | $110K |
| Jan 23, 2026 | Nolan Sean P.Chief Executive Officer | Sell | 136,789 | $4.75 | $650K |
| Jan 23, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 89,132 | $4.75 | $423K |
| Jan 23, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sell | 78,968 | $4.75 | $375K |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Sell | 200,000 | $4.71 | $942K |
| Dec 1, 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 260,047 | $4.51 | $1.2M |
| Nov 28, 2025 | Nagendran SukumarPresident and Head of R&D | Sell | 110,125 | $4.75 | $523K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance